Taking into consideration the importance of MAPK in CML, specific inhibitors for BCR-ABL tyrosine kinase activity have been designed and are being developed for treating CML [15]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.